This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

OncoMed Announces Abstracts Accepted At The 2014 ASCO Annual Meeting

Stocks in this article: OMED

REDWOOD CITY, Calif., April 23, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that several abstracts have been accepted for presentation at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting being held May 30 – June 3, 2014 in Chicago, IL.

OncoMed will present new clinical data from its ongoing studies, including the Phase 1b study of demcizumab (OMP-21M18, anti-DLL4) in non-small cell lung cancer (NSCLC), the Phase 1/2 PINNACLE trial of OMP-59R5 (anti-Notch 2/3) in small-cell lung cancer (SCLC) and the Phase 1 trial of OMP-54F28 (FZD8-Fc) in patients with advanced solid tumors. The list of abstracts and timing of the presentations is provided below.

Oral Presentation

  • A first-in-human Phase 1 study of anti-cancer stem cell agent OMP-54F28 (FZD8-Fc), decoy receptor for WNT ligands, in patients with advanced solid tumors. ( Abstract# 2505)

Presenting author: Antonio Jimeno M.D., Ph.D., University of Colorado Cancer Center Date and time: Saturday, May 31, 2014 at 1:15 PM – 4:15 PM CDT Session: Oral Abstract Session - Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics

Posters

  • Phase 1b of anti-cancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with etoposide and cisplatin (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). ( Abstract# 7601)

Presenting author: David R. Spigel, M.D., Sarah Cannon Research Institute Date and time: Saturday, May 31, 2014 at 1:15 PM – 5:00 PM CDT Session: General Poster Session - Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers

  • A Phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquamous NSCLC. ( Abstract # 2544)

Presenting author: Mark McKeage, MBChB, MMedSc, Ph.D., FRACP, University of Auckland

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs